Makale detayı · 2019
QbD guided early pharmaceutical development study: Production of lipid nanoparticles by high pressure homogenization for skin cancer treatment
YÖKSİS
OpenAlex
SJR Q1
JCR Q1
Atıf 106
Üst %10
Yüzdelik 95.3%
FWCI 4.14
- Yıl
- 2019
- Tür
- article
Veri kaynağı ayrımı
- YÖKSİS YÖKSİS makale kaydı
- YÖKSİS dergi adı International Journal of Pharmaceutics
- Katalog eşleşmesi (ISSN) International Journal of Pharmaceutics
- OpenAlex OpenAlex zenginleştirmesi (özet, atıf, konular)
Özet
Özet henüz derlenmedi; DergiPark / OpenAlex kuyruğu işlenince burada görünecek.
Konular
Atıflar
OpenAlex cited_by_count. WoS veya Scopus atıf sayısı değildir; o kaynaklar için ayrı kolon yoktur.
106 atıf
OpenAlex cited_by_count (önbellek / veritabanı)
Yerel katalogda bu makaleye atıf yapan 13 yayın (OpenAlex referans eşleşmesi; tam dünya listesi değildir).
- QbD based formulation optimization of semi-solid lipid nanoparticles as nano-cosmeceuticals 2021
- QbD based formulation optimization of semi-solid lipid nanoparticles as nano-cosmeceuticals 2021
- An Innovative Formulation Based on Nanostructured Lipid Carriers for Imatinib Delivery: Pre-Formulation, Cellular Uptake and Cytotoxicity Studies 2022
- An Innovative Formulation Based on Nanostructured Lipid Carriers for Imatinib Delivery: Pre-Formulation, Cellular Uptake, and Cytotoxicity Studies 2022
- An Innovative Formulation Based on Nanostructured Lipid Carriers for Imatinib Delivery: Pre-Formulation, Cellular Uptake and Cytotoxicity Studies. 2022
- An Innovative Formulation Based on Nanostructured Lipid Carriers for Imatinib Delivery: Pre-Formulation, Cellular Uptake and Cytotoxicity Studies 2022
- A study to enhance the oral bioavailability of s-adenosyl-l-methionine (SAMe): SLN and SLN nanocomposite particles 2021
- A study to enhance the oral bioavailability of s-adenosyl-l-methionine (SAMe): SLN and SLN nanocomposite particles 2021
- A Study to Enhance the Oral Bioavailability of S-Adenosyl-L-Methionine (SAME): SLN and SLN Nanocomposite Particles 2021
- A study to enhance the oral bioavailability of s-adenosyl-l-methionine (SAMe): SLN and SLN nanocomposite particles 2021